US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Brookfield Real Assets Income Fund Inc.

12.53

+0.02000.16%

Post-market: 12.530.00000.00%16:15 EDT

Volume:117.86K

Turnover:1.48M

Market Cap:692.34M

PE:10.62

High:12.55

Open:12.55

Low:12.51

Close:12.51

52wk High:13.59

52wk Low:12.50

Shares:55.25M

Float Shares:55.25M

Volume Ratio:0.76

T/O Rate:0.21%

Dividend:1.42

Dividend Rate:11.30%

EPS(TTM):1.18

ROE:--

ROA:--

PB:0.87

PE(LYR):- -

Loading ...

Overview Company News Filings

Astellas Wraps Up Real-World Safety Study on Smyraf, Clarifying RA Market Outlook

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

Brookfield Real Assets Income Fund names Oaktree’s Aaron Greenberg to run securitized credit allocation

Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China

Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Can IMVT-1402’s Phase 2 RA Data Reframe Immunovant’s (IMVT) Autoimmune Pipeline Narrative?

Simply Wall St.

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA

Pell Bio Med Unit Gets China's Regulatory Nod for Rheumatoid Arthritis Drug Trail

MT Newswires Live

Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Brookfield Real Assets director Heather S. Goldman disposes 2,750 shares for $34,980.84

Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance

Tyler Van Buren Reiterates Buy on Artiva, Citing Strong AlloNK RA Efficacy and Funded Path to Registrational Trial

Press Release: Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/RA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","market":"US","secType":"STK","nameCN":"Brookfield Real Assets Income Fund Inc.","latestPrice":12.53,"timestamp":1788379200000,"preClose":12.51,"halted":0,"volume":117862,"hourTrading":{"tag":"盘后","latestPrice":12.53,"preClose":12.53,"latestTime":"16:15 EDT","volume":13,"amount":162.8614,"timestamp":1788380100276,"change":0,"changeRate":0,"amplitude":0.002283},"delay":0,"changeRate":0.0015987210231814208,"floatShares":55245934,"shares":55254696,"eps":1.18,"marketStatus":"Post-Mkt","change":0.02,"latestTime":"09-02 17:11:06 EDT","open":12.55,"high":12.55,"low":12.51,"amount":1475618,"amplitude":0.003197,"askPrice":12.97,"askSize":5,"bidPrice":12.5,"bidSize":50,"shortable":3,"etf":0,"ttmEps":1.18,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788393600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":12.51,"dividendRate":0.112961,"preHourTrading":{"tag":"盘前","latestPrice":12.51,"preClose":12.51,"latestTime":"07:36 EDT","volume":1,"amount":12.51,"timestamp":1788349016041,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":12.53,"preClose":12.53,"latestTime":"16:15 EDT","volume":13,"amount":162.8614,"timestamp":1788380100276,"change":0,"changeRate":0,"amplitude":0.002283},"volumeRatio":0.759054},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","floatShares":55245934,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.759054,"shares":55254696,"dividePrice":1.4154,"high":12.55,"amplitude":0.003197,"preClose":12.51,"low":12.51,"week52Low":12.5,"pbRate":"0.87","week52High":13.59,"institutionHeld":0,"latestPrice":12.53,"committee":0.818182,"eps":1.18,"divideRate":0.112961,"volume":117862,"delay":0,"ttmEps":1.18,"open":12.55,"prevYearClose":12.96,"prevWeekClose":12.62,"prevMonthClose":12.55,"prevQuarterClose":12.88,"fiveDayClose":12.63,"twentyDayClose":12.9,"sixtyDayClose":12.73},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RA\",params:#limit:5,,,undefined,":[{"date":"2026-09-10","symbol":"RA","amount":0.118,"announcedDate":"2026-06-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-10","defaultRemindTime":1789047000000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-24","payableDate":"2026-09-10","currency":"USD","dateTimestamp":1789012800000,"payDate":"2026-09-24"},{"date":"2026-08-06","symbol":"RA","amount":0.118,"announcedDate":"2026-06-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-06","defaultRemindTime":1786023000000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-20","payableDate":"2026-08-06","currency":"USD","dateTimestamp":1785988800000,"payDate":"2026-08-20"},{"date":"2026-07-09","symbol":"RA","amount":0.118,"announcedDate":"2026-06-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-09","defaultRemindTime":1783603800000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-23","payableDate":"2026-07-09","currency":"USD","dateTimestamp":1783569600000,"payDate":"2026-07-23"},{"date":"2026-06-11","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-11","defaultRemindTime":1781184600000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-25","payableDate":"2026-06-11","currency":"USD","dateTimestamp":1781150400000,"payDate":"2026-06-25"},{"date":"2026-05-07","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-07","defaultRemindTime":1778160600000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-21","payableDate":"2026-05-07","currency":"USD","dateTimestamp":1778126400000,"payDate":"2026-05-21"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RA\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-13","recordDate":"2016-12-15","paymentDate":"2016-12-22","value":0.199,"currency":"USD"},{"executeDate":"2017-03-14","recordDate":"2017-03-16","paymentDate":"2017-03-23","value":0.199,"currency":"USD"},{"executeDate":"2017-04-18","recordDate":"2017-04-20","paymentDate":"2017-04-27","value":0.199,"currency":"USD"},{"executeDate":"2017-05-16","recordDate":"2017-05-18","paymentDate":"2017-05-25","value":0.199,"currency":"USD"},{"executeDate":"2017-06-13","recordDate":"2017-06-15","paymentDate":"2017-06-22","value":0.199,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2642201544","title":"Astellas Wraps Up Real-World Safety Study on Smyraf, Clarifying RA Market Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2642201544","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642201544?lang=en_us&edition=fundamental","pubTime":"2026-06-11 00:31","pubTimestamp":1781109096,"startTime":"0","endTime":"0","summary":"Astellas Pharma ($ALPMF) announced an update on their ongoing clinical study. The Japan Post-Marketing Surveillance – Specified Drug Use-results Su...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/astellas-wraps-up-real-world-safety-study-on-smyraf-clarifying-ra-market-outlook?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/astellas-wraps-up-real-world-safety-study-on-smyraf-clarifying-ra-market-outlook?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642442360","title":"Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2642442360","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642442360?lang=en_us&edition=fundamental","pubTime":"2026-06-10 19:30","pubTimestamp":1781091000,"startTime":"0","endTime":"0","summary":"CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) CLN-978 data from the first RA mul","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/10/3309602/0/en/Cullinan-Therapeutics-Shares-New-Clinical-Data-Across-Its-Portfolio-of-T-Cell-Engager-Programs-Targeting-CD19-and-BCMA-in-Autoimmune-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM","CRS","RA","BK4077","ITP","IE00B66KJ199.SGD","IE00B7SZL793.SGD","LU0963586101.USD","SLE","BK4139","IE0031619046.USD","BK4187","BK4006","IE00B19Z4B17.USD","LU2065731478.USD","BK4199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642435973","title":"Brookfield Real Assets Income Fund names Oaktree’s Aaron Greenberg to run securitized credit allocation","url":"https://stock-news.laohu8.com/highlight/detail?id=2642435973","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642435973?lang=en_us&edition=fundamental","pubTime":"2026-06-09 01:20","pubTimestamp":1780939208,"startTime":"0","endTime":"0","summary":"Brookfield Real Assets Income Fund announced a portfolio manager change for its securitized credit allocation at sub-adviser Oaktree, effective June 30, 2026.Justin Guichard will step down from the role. Aaron Greenberg will take over.Greenberg is a managing director at Oaktree. He was named portfolio manager for Oaktree’s Real Estate Debt strategy, co-portfolio manager for Structured Credit.Greenberg previously worked as a CMBS trader at Morgan Stanley. He later led Deutsche Bank’s secondary trading desk.Co-portfolio managers Gaal Surugeon, Chris Janus, Riley O’Neil will remain responsible for day-to-day management and strategic allocation decisions.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDLbBM72w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","BK4112","LU2095319765.USD","IE00BGHQF748.EUR","LU2210149790.SGD","IE00BN0W2V16.EUR","LU0314104364.USD","BK4588","IE00BN0W2T93.GBP","NDAQ","LU2210150020.SGD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","BK4585","SG9999014039.USD","RA","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014005.SGD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641484542","title":"Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2641484542","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641484542?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:31","pubTimestamp":1780921860,"startTime":"0","endTime":"0","summary":"First regulatory approval for Sjgren’s disease (SjD) First and only approved therapy for SjD in China Approval based on positive Phase 3 results generated by collaborator RemeGen demonstrating statist","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/08/3308123/0/en/Telitacicept-Receives-NMPA-Approval-for-the-Treatment-of-Sj%C3%B6gren-s-Disease-in-China.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE","RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641489805","title":"Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses","url":"https://stock-news.laohu8.com/highlight/detail?id=2641489805","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641489805?lang=en_us&edition=fundamental","pubTime":"2026-06-08 19:00","pubTimestamp":1780916400,"startTime":"0","endTime":"0","summary":"KT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and clinically active therapies in multiple preclinical lupus models KT-579 Phase 1 healthy volunteer trial","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/08/3307932/0/en/Kymera-Therapeutics-Presents-New-Preclinical-Lupus-Data-for-KT-579-First-in-Class-Oral-IRF5-Degrader-at-EULAR-and-FOCIS-Congresses.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBD","LU0541501648.USD","LU0541502299.USD","KYMR","BK4115","BK4139","RA","SG9999004220.SGD","KT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641450485","title":"Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2641450485","media":"GlobeNewswire","labels":["policyRegulatory","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641450485?lang=en_us&edition=fundamental","pubTime":"2026-06-08 18:30","pubTimestamp":1780914600,"startTime":"0","endTime":"0","summary":"Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjgren disease and systemic sclerosi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/08/3307910/0/en/Artiva-Biotherapeutics-Highlights-AlloNK-Data-Presented-at-EULAR-2026-FDA-RMAT-Designation-in-Refractory-Rheumatoid-Arthritis-and-Webcast-Today.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z4B17.USD","LABU","BK4187","BK4006","IE00B66KJ199.SGD","LU2065731478.USD","BK4139","IE0031619046.USD","BK4585","LU0963586101.USD","BK4588","CRS","IE00B7SZL793.SGD","ARTV","RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641179545","title":"Can IMVT-1402’s Phase 2 RA Data Reframe Immunovant’s (IMVT) Autoimmune Pipeline Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2641179545","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641179545?lang=en_us&edition=fundamental","pubTime":"2026-06-08 01:13","pubTimestamp":1780852390,"startTime":"0","endTime":"0","summary":"Recent commentary on Immunovant’s IMVT-1402 program highlighted high response rates in a completed Phase 2 rheumatoid arthritis trial, including in patients who had already received multiple advanced therapies.\nThis focus on difficult-to-treat patients has pushed IMVT-1402 to the center of Immunovant’s story, raising questions about how such response rates could shape expectations for its broader autoimmune pipeline.\nWe’ll now look at how the strong IMVT-1402 Phase 2 responses in difficult...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/can-imvt-1402s-phase-2-ra-data-reframe-immunovants-imvt-auto","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/can-imvt-1402s-phase-2-ra-data-reframe-immunovants-imvt-auto","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IMVT","BK4585","BK4588","RA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641290111","title":"Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2641290111","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641290111?lang=en_us&edition=fundamental","pubTime":"2026-06-06 17:15","pubTimestamp":1780737300,"startTime":"0","endTime":"0","summary":"Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 Deep, dose-dependent B ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/06/3307681/0/en/Cullinan-Therapeutics-Presents-Initial-Clinical-Data-for-CLN-978-a-CD19xCD3-T-Cell-Engager-at-the-EULAR-2026-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","IE00B19Z4B17.USD","LU2065731478.USD","IE00B7SZL793.SGD","LU0963586101.USD","BK4139","IE0031619046.USD","IE00B66KJ199.SGD","SLE","BK4187","BK4006","RA","CRS","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640090118","title":"Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA","url":"https://stock-news.laohu8.com/highlight/detail?id=2640090118","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640090118?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:00","pubTimestamp":1780488000,"startTime":"0","endTime":"0","summary":"Enrollment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of the SKYWAY basket trial are complete Company reiterates expected Q3 2026 readout for rheumatoid arthritis (R","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/03/3305970/0/en/Spyre-Therapeutics-Announces-Completion-of-Enrollment-in-SKYWAY-Basket-Trial-Evaluating-SPY072-anti-TL1A-in-RA-PsA-and-axSpA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CIA","BK4007","RA","BK4162","SYRE","BK4539","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640072973","title":"Pell Bio Med Unit Gets China's Regulatory Nod for Rheumatoid Arthritis Drug Trail","url":"https://stock-news.laohu8.com/highlight/detail?id=2640072973","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640072973?lang=en_us&edition=fundamental","pubTime":"2026-06-03 12:48","pubTimestamp":1780462082,"startTime":"0","endTime":"0","summary":"Pell Bio Med Technology  unit Peptide  Pharmaceutical Technology secured approval from China's National Medical Products Administration  to begin the Phase I clinical trial for its oral drug candidate PP011, according to a Tuesday Taiwan Exchange filing.The trial will be conducted in healthy subjects and targets rheumatoid arthritis , marking the first human study for the novel therapy.The company said the development program is planned through Phase two and Phase three trials before potential new drug application submission.Phase one completion is expected in the first quarter of 2027, it said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636685524","title":"Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2636685524","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636685524?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:00","pubTimestamp":1779192000,"startTime":"0","endTime":"0","summary":"Veteran biotechnology executive with more than 20 years of leadership experience spanning research, clinical development, commercialization and company building Proven track record advancing multiple ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/19/3297380/0/en/Artiva-Biotherapeutics-Appoints-Veteran-Biotech-Executive-and-Drug-Developer-Diego-Miralles-M-D-as-President-and-Head-of-Research-and-Development.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","RA","ARTV","XBI","BK4139","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636014880","title":"Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2636014880","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636014880?lang=en_us&edition=fundamental","pubTime":"2026-05-19 05:00","pubTimestamp":1779138000,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., May  18, 2026  (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc.(Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/18/3297050/0/en/Cullinan-Therapeutics-to-Present-Initial-Clinical-Data-for-CLN-978-in-Treatment-Refractory-Rheumatoid-Arthritis-and-Systemic-Lupus-Erythematosus-at-EULAR-2026-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","RA","CGEM","SLE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635772596","title":"First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635772596","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635772596?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:15","pubTimestamp":1778789700,"startTime":"0","endTime":"0","summary":"First Tracks launched April 20th with a two-year cash-runway to advance ANB033 through celiac disease and eosinophilic esophagitis Phase 1b data and plans to initiate Phase 2 trials across four indica","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3295401/0/en/First-Tracks-Biotherapeutics-Announces-First-Quarter-2026-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635814748","title":"Brookfield Real Assets director Heather S. Goldman disposes 2,750 shares for $34,980.84","url":"https://stock-news.laohu8.com/highlight/detail?id=2635814748","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635814748?lang=en_us&edition=fundamental","pubTime":"2026-05-14 21:10","pubTimestamp":1778764255,"startTime":"0","endTime":"0","summary":"Director Heather S. Goldman sold 2,750 shares of Brookfield Real Assets Income Fund common stock on May 13 at USD 12.72.Direct holdings fell to 21 shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brookfield Real Assets Income Fund Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 14, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL8vLx3Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Brookfield Real Assets director Heather S. Goldman disposes 2,750 shares for $34,980.84","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635171647","title":"Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2635171647","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635171647?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:30","pubTimestamp":1778761800,"startTime":"0","endTime":"0","summary":"Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable through treatment Results further support the potential for telitacicept t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3294940/0/en/Vor-Bio-Announces-Publication-of-Interim-Analysis-of-TELIGAN-a-China-Phase-3-Trial-of-Telitacicept-in-IgA-Nephropathy-in-The-New-England-Journal-of-Medicine.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE","RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635782088","title":"Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2635782088","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635782088?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:30","pubTimestamp":1778675400,"startTime":"0","endTime":"0","summary":"RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initia","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293996/24675/en/Fate-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125154778.USD","LU1221951046.USD","BK4080","LU2133065610.SGD","LU2237443622.USD","LU2746668974.SGD","FATE","IE00BLSP4239.USD","LU1920063259.USD","SG9999011175.SGD","LU0912757837.SGD","LU1920062954.HKD","LU1894683348.USD","IIM","IE00BBT3K403.USD","LU0949170772.SGD","RA","LU0795875086.SGD","LU2125154935.USD","BK4581","LU2506951875.HKD","CMC","LU1868837136.USD","SITC","LU0971096721.USD","LU2237443465.HKD","LU0170899867.USD","BK4504","IE00BVYPNW00.USD","IND","LU1868836591.USD","BK4139","LU0882574139.USD","CAR","LU1732799900.SGD","LU1894683264.USD","BK4559","SG9999014567.USD","BK4533","LU0096364046.USD","LU1670711123.USD","LU2347655156.SGD","SLE","LU0289960550.SGD","SG9999014559.SGD","IE00B3PB1722.GBP","LU0545039389.USD","KO","LU0098860793.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635782086","title":"Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635782086","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635782086?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:30","pubTimestamp":1778675400,"startTime":"0","endTime":"0","summary":"Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of teli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3294002/0/en/Vor-Bio-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","RA","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634404286","title":"Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2634404286","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634404286?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:00","pubTimestamp":1778500800,"startTime":"0","endTime":"0","summary":"Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF (+27%) and APONVIE (+50%)Q1 2026 total net revenue of $34.7 millionReached settlement with Baxter Healthca","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/11/3291812/0/en/Heron-Therapeutics-Announces-First-Quarter-2026-Financial-Results-and-Reaffirms-Guidance.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","HRTX","BK4211","BK4195","RA","CINV","BK4139","MEC","BK4563","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634880832","title":"Tyler Van Buren Reiterates Buy on Artiva, Citing Strong AlloNK RA Efficacy and Funded Path to Registrational Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2634880832","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634880832?lang=en_us&edition=fundamental","pubTime":"2026-05-11 18:55","pubTimestamp":1778496919,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ARTV stock, giving a Buy rating on May 8. Tyler Van Buren has given his Buy...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/tyler-van-buren-reiterates-buy-on-artiva-citing-strong-allonk-ra-efficacy-and-funded-path-to-registrational-trial-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/tyler-van-buren-reiterates-buy-on-artiva-citing-strong-allonk-ra-efficacy-and-funded-path-to-registrational-trial-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RA","BK4588","LU0390134368.USD","BK4023","BK4585","LU1989773731.SGD","ARTV","LU1989763005.USD","TYL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633943274","title":"Press Release: Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2633943274","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633943274?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:31","pubTimestamp":1778236260,"startTime":"0","endTime":"0","summary":"Initial AlloNK  clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis  patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no patients relapsing or requiring new immunomodulatory agents. AlloNK treatment regimen demonstrated a consistent pattern of deep B-cell depletion and tolerability results supportive of outpatient administration in community rheumatology settings. U.S. Food and Drug Administration  alignment on a single Phase 3 registrational randomized controlled trial evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 refractory RA patients, with ACR50 at six months as the primary endpoint; trial initiation planned for H2 2026. Multiple oral and poster presentations at EULAR 2026, including a late-breaking oral presentation on AlloNK clinical efficacy in refractory RA, Sjgren disease  and systemic sclerosis . autoimmune diseases. The broader autoimmune dataset also included 11","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV","RA","BK4232","R","BK4022","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":57,"code":"91000000","status":"200"}]}}